Improved Survival in Unresectable Neuroblastoma with Chemotherapy
Author Information
Author(s): H Rubie, J Michon, D Plantaz, MC Peyroulet, C Coze, D Frappaz, P Chastagner, MC Baranzelli, F Mechinaud, P Boutard, P Lutz, Y Perel, G Leverger, L de Lumley, F Millot, JL Stephan, G Margueritte, O Hartmann
Primary Institution: Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP)
Hypothesis
The study aims to assess the efficacy and safety of primary chemotherapy including carboplatin and etoposide in children with unresectable neuroblastoma.
Conclusion
The combination of carboplatin and etoposide followed by CAdO chemotherapy shows encouraging results in improving survival rates for children with localized but unresectable neuroblastoma.
Supporting Evidence
- Overall response rate to chemotherapy was 71%.
- 5-year overall survival rate was 88% and event-free survival rate was 78%.
- Children without N-myc amplification had survival rates comparable to those with resectable tumors.
Takeaway
Kids with a tough type of cancer called neuroblastoma can do better with special medicine that helps them survive, even if the cancer can't be removed by surgery.
Methodology
The study involved 130 children with unresectable neuroblastoma who received primary chemotherapy consisting of carboplatin-etoposide and vincristine-cyclophosphamide-doxorubicin, followed by surgical evaluation.
Potential Biases
Potential bias in patient selection as the definition of unresectable tumours relied on imaging rather than operative findings.
Limitations
The study may have included some cases with undetected metastatic disease due to reliance on imaging for defining unresectability.
Participant Demographics
Children aged 0 to 16 years, with a median age of 14 months.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website